Metropolitan Life Insurance Company (MetLife)’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio GTHX Stock Details GTHX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,729	Closed	-$20.7K	–	2448
2022 Q1	$20.7K	Sell	2,729 -4,137	-60%	-$39.2K	﹤0.01%	2077
2021 Q4	$70.1K	Sell	6,866 -1,576	-19%	-$20.1K	﹤0.01%	2637
2021 Q3	$113K	Sell	8,442 -2,645	-24%	-$43.1K	﹤0.01%	2462
2021 Q2	$243K	Hold	11,087	–	–	﹤0.01%	2007
2021 Q1	$267K	Hold	11,087	–	–	﹤0.01%	1817
2020 Q4	$199K	Hold	11,087	–	–	﹤0.01%	1937
2020 Q3	$128K	Hold	11,087	–	–	﹤0.01%	2079
2020 Q2	$269K	Hold	11,087	–	–	﹤0.01%	1617
2020 Q1	$122K	Hold	11,087	–	–	﹤0.01%	1903
2019 Q4	$293K	Sell	11,087 -513	-4%	-$12K	﹤0.01%	1651
2019 Q3	$264K	Buy	11,600 +3,935	+51%	+$124K	﹤0.01%	1684
2019 Q2	$235K	Hold	7,665	–	–	﹤0.01%	1793
2019 Q1	$127K	Hold	7,665	–	–	﹤0.01%	2179
2018 Q4	$147K	Buy	7,665 +847	+12%	+$31.7K	﹤0.01%	2020
2018 Q3	$357K	Hold	6,818	–	–	0.01%	1610
2018 Q2	$296K	Buy	6,818 +2,224	+48%	+$95.3K	﹤0.01%	1675
2018 Q1	$170K	Buy	+4,594	New	+$123K	﹤0.01%	1992

Other funds holding GTHX

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s GTHX Position: Q2 2022 in Review

Metropolitan Life Insurance Company (MetLife) sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q2 2022, closing a stake of 2,729 shares — an estimated $20.7K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in GTHX in Q1 2018 and held it in 17 quarters. The position peaked at $357K in Q3 2018. 98 funds tracked by Wall St. Rank hold GTHX as of Q2 2022.

Metropolitan Life Insurance Company (MetLife) reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 2,729 G1 Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $20.7K.
Metropolitan Life Insurance Company (MetLife) first reported a position in G1 Therapeutics, Inc. Common Stock in Q1 2018 and held it in 17 quarters.
Metropolitan Life Insurance Company (MetLife)'s G1 Therapeutics, Inc. Common Stock position peaked at $357K in Q3 2018.
98 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2022, filed 11 Aug 2022.